Sacubitrilcalcium , ≥98%(HPLC) , 1369773-39-6

Synonym(s):
(2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic acid ethyl ester;4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt;4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid; (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester;AHU377 calcium salt;AHU-377 calcium salt

CAS NO.：1369773-39-6

Empirical Formula: C48H56CaN2O10

Molecular Weight: 861.044

MDL number: MFCD28137893

PRODUCT Properties

• Melting point: >140°C (dec.)
• Density: 1.24g/cm3 at 20℃
• vapor pressure: 0.001Pa at 20℃
• storage temp.: -20°C
• solubility: DMSO (Slightly, Heated), Methanol (Slightly)
• form: powder
• color: white to beige
• optical activity: -16.3°(C=0.01g/mL,MEOH, 20°C, 589nm)
• InChIKey: DDLCKLBRBPYKQS-AGIGYYLVNA-L
• LogP: -0.66-2.9 at 20℃ and pH2-7

Description and Uses

Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug, valsartan/sacubitril, known during trials as LCZ696 and marketed under the brand name, Entresto, is a treatment for heart failure.

Safety

• Symbol(GHS): GHS06,GHS09
• Signal word: Danger
• Hazard statements: H301-H400
• Precautionary statements: P273-P301+P310+P330
• RIDADR: UN2811 - class 6.1 - PG 3 - EHS - Toxic solids, organic, n.o.s., HI: all